Mebanazine-d5
CAS : 65-64-5
Ref. 3D-AAA06564
1mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté | ||
250mg | Arrêté |
Informations sur le produit
- (1-Phenylethyl)Hydrazine
- (α-Methylbenzyl)hydrazine
- 1-(1-Phenylethyl)hydrazine
- Actamol
- Hydrazine, (1-phenylethyl)-
- Hydrazine, (α-methylbenzyl)-
- Mebanazine
Mebanazine-d5 is a drug that is used to treat Parkinson's disease. It is a dopamine receptor antagonist that blocks the binding of dopamine to its receptor and inhibits the production of IL-2. Mebanazine-d5 has been shown to have genotoxic effects in an in vitro study with human lymphocytes, where it induced chromosomal aberrations and DNA strand breakage. Mebanazine-d5 also showed acute toxicities in mice at oral doses of 600 mg/kg, including lethargy, loss of balance, and ataxia. This drug may inhibit the activity of nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, by competing for ileum uptake sites on cells lining the small intestine.